Asteria Luzardo-Álvarez

Dr. Asteria Luzardo-Álvarez

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
RVRubén Varela-Fernández
Rubén Varela-Fernández
VTVictoria Díaz Tomé
Victoria Díaz Tomé
ALAndrea Luaces-Rodríguez
Andrea Luaces-Rodríguez
ACAndrea Conde-Penedo
Andrea Conde-Penedo
Xurxo García-OteroXurxo García-Otero
Xurxo García-Otero
Francisco Otero-EspinarFrancisco Otero-Espinar
Francisco Otero-Espinar
The treatment of the posterior-segment ocular diseases, such as age-related eye diseases (AMD) or diabetic retinopathy (DR), present a challenge for ophthalmologists due to the complex anatomy and physiology of the eye. This specialized organ is composed of various static and dynamic barriers that restrict drug delivery into the target site of action. Despite numerous efforts, effective intraocular drug delivery remains unresolved and, therefore, it is highly desirable to improve the current treatments of diseases affecting the posterior cavity. This review article gives an overview of pharmacokinetic and biopharmaceutics aspects for the most commonly-used ocular administration routes (intravitreal, topical, systemic, and periocular), including information of the absorption, distribution, and elimination, as well as the benefits and limitations of each one. This article also encompasses different conventional and novel drug delivery systems designed and developed to improve drug pharmacokinetics intended for the posterior ocular segment treatment.

1 April 2006 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
USUlf Siemoneit
Ulf Siemoneit
CSChristoph Schmitt
Christoph Schmitt
Carmen Alvarez-LorenzoCarmen Alvarez-Lorenzo
Carmen Alvarez-Lorenzo
ALAsteria Luzardo-Álvarez
Asteria Luzardo-Álvarez
Francisco Otero-EspinarFrancisco Otero-Espinar
Francisco Otero-Espinar
JBJosé Blanco-Méndez
José Blanco-Méndez

1 June 2004 in Aquaculture
Verified
Journal Article
Closed access
Jesus L. RomaldeJesus L. Romalde
Jesus L. Romalde
ALAsteria Luzardo-Álvarez
Asteria Luzardo-Álvarez
CRCarmen Ravelo
Carmen Ravelo
ATAlicia E. Toranzo
Alicia E. Toranzo
JBJosé Blanco-Méndez
José Blanco-Méndez

2 December 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
ISIria Seoane-Viaño
Iria Seoane-Viaño
NGNoemí Gómez-Lado
Noemí Gómez-Lado
HLHéctor Lázare-Iglesias
Héctor Lázare-Iglesias
Xurxo García-OteroXurxo García-Otero
Xurxo García-Otero
JAJosé Ramón Antúnez-López
José Ramón Antúnez-López
Anxo Fernández-FerreiroAnxo Fernández-Ferreiro
Anxo Fernández-Ferreiro
The aim of this study was to fabricate novel self-supporting tacrolimus suppositories using semisolid extrusion 3-dimensional printing (3DP) and to investigate their efficacy in an experimental model of inflammatory bowel disease. Blends of Gelucire 44/14 and coconut oil were employed as lipid excipients to obtain suppository formulations with self-emulsifying properties, which were then tested in a TNBS (2,4,6-trinitrobenzenesulfonic acid) induced rat colitis model. Disease activity was monitored using PET/CT medical imaging; maximum standardized uptake values (SUVmax), a measure of tissue radiotracer accumulation rate, together with body weight changes and histological assessments, were used as inflammatory indices to monitor treatment efficacy. Following tacrolimus treatment, a significant reduction in SUVmax was observed on days 7 and 10 in the rat colon sections compared to non-treated animals. Histological analysis using Nancy index confirmed disease remission. Moreover, statistical analysis showed a positive correlation (R2 = 71.48%) between SUVmax values and weight changes over time. Overall, this study demonstrates the effectiveness of 3D printed tacrolimus suppositories to ameliorate colitis and highlights the utility of non-invasive PET/CT imaging to evaluate new therapies in the preclinical area.

1 December 2005 in Journal of Controlled Release
Verified
Journal Article
Closed access
ALAsteria Luzardo-Álvarez
Asteria Luzardo-Álvarez
NBNatalia Blarer
Natalia Blarer
KPKatrin Peter
Katrin Peter
JRJackeline F. Romero
Jackeline F. Romero
CRChristophe Reymond
Christophe Reymond
BGBruno Gander
Bruno Gander

1 February 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
EBE. Blanco-García
E. Blanco-García
Francisco Otero-EspinarFrancisco Otero-Espinar
Francisco Otero-Espinar
JBJ. Blanco-Méndez
J. Blanco-Méndez
JLJosé M. Leiro-Vidal
José M. Leiro-Vidal
ALAsteria Luzardo-Álvarez
Asteria Luzardo-Álvarez